KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Biogen (BIIB) EBITDA (2016 - 2025)

Historic EBITDA for Biogen (BIIB) over the last 17 years, with Q4 2025 value amounting to -$551.5 million.

  • Biogen's EBITDA fell 8886.99% to -$551.5 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$847.7 million, marking a year-over-year decrease of 10961.92%. This contributed to the annual value of -$847.7 million for FY2025, which is 10961.92% down from last year.
  • Biogen's EBITDA amounted to -$551.5 million in Q4 2025, which was down 8886.99% from -$117.1 million recorded in Q3 2025.
  • Biogen's EBITDA's 5-year high stood at $973.9 million during Q1 2021, with a 5-year trough of -$800.8 million in Q3 2023.
  • Over the past 5 years, Biogen's median EBITDA value was $74.1 million (recorded in 2022), while the average stood at $134.1 million.
  • In the last 5 years, Biogen's EBITDA soared by 27758.62% in 2021 and then crashed by 109300.91% in 2023.
  • Biogen's EBITDA (Quarter) stood at $587.1 million in 2021, then tumbled by 94.4% to $32.9 million in 2022, then crashed by 1093.01% to -$326.7 million in 2023, then rose by 10.62% to -$292.0 million in 2024, then plummeted by 88.87% to -$551.5 million in 2025.
  • Its EBITDA was -$551.5 million in Q4 2025, compared to -$117.1 million in Q3 2025 and $139.0 million in Q2 2025.